Topic Hub
24 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 24 of 24 clinical reviews.
Does alprostadil (Caverject, MUSE) affect appetite or food cravings? A physician-reviewed deep dive into the pharmacology, clinical trial data, and patient reporting around alprostadil and appetite changes.
Read clinical reviewA physician-level review of alprostadil pharmacology, efficacy, and safety in patients with autoimmune conditions including lupus, rheumatoid arthritis, Sjogren syndrome, and vasculitis. Includes dosing, contraindications, and clinical decision guidance.
Read clinical reviewA physician-reviewed analysis of alprostadil's effects on bone metabolism, density, and fracture risk in men with erectile dysfunction, with primary-literature citations and clinical guidance.
Read clinical reviewA clinician-level review of the available pharmacovigilance data, mechanistic arguments, and primary literature on whether alprostadil (Caverject, MUSE) carries a meaningful cancer risk signal for men using it to treat erectile dysfunction.
Read clinical reviewA clinician-level review of alprostadil's long-term cardiovascular effects, hemodynamic profile, safety data, and prescribing considerations for men with erectile dysfunction and concurrent cardiac disease.
Read clinical reviewA clinician-level review of alprostadil's effects on cognitive function, covering prostaglandin E1 neurophysiology, evidence from ED and cerebrovascular trials, dosing, and what patients should realistically expect.
Read clinical reviewA physician-reviewed comparison of compounded alprostadil versus branded Caverject and MUSE for refractory erectile dysfunction, covering efficacy, safety, cost, regulatory status, and how to choose the right formulation.
Read clinical reviewA GRADE-graded review of alprostadil (Caverject, MUSE) for refractory erectile dysfunction: key trials, mechanism, dosing, safety, and clinical decision-making at PharmD/MD depth.
Read clinical reviewA physician-reviewed guide to the dermatologic effects of alprostadil injection and suppository therapy, including hair changes, skin reactions, and clinical management strategies.
Read clinical reviewA physician-level review of whether alprostadil (Caverject, MUSE) affects liver function, including pharmacokinetic data, clinical trial evidence, and dosing guidance for patients with hepatic impairment.
Read clinical reviewA physician-level review of how alprostadil affects mental health and mood in men with erectile dysfunction, covering psychogenic ED, anxiety, relationship quality, and clinical trial data.
Read clinical reviewA physician-level review of how alprostadil is absorbed, distributed, metabolized, and eliminated, plus its documented effects on local and systemic energy expenditure. Includes dosing, pharmacokinetics, and clinical trial data.
Read clinical reviewA clinician-level review of alprostadil microdosing protocols for erectile dysfunction, covering intracavernosal and intraurethral dose titration, combination regimens, and the primary-literature evidence base for sub-standard dosing strategies.
Read clinical reviewA clinician-level guide to alprostadil muscle preservation strategies for patients using Caverject or MUSE, covering injection technique, fibrosis prevention, dose titration, and long-term penile tissue health based on primary literature.
Read clinical reviewA clinician-level guide to diagnosing and correcting alprostadil plateau and non-response in men with refractory erectile dysfunction, including dose optimization, combination strategies, and when to escalate care.
Read clinical reviewA clinician-level review of alprostadil (Caverject, MUSE) for erectile dysfunction after bariatric surgery, covering pharmacology, dosing adjustments, efficacy data, and practical management considerations.
Read clinical reviewA clinician-level guide to managing alprostadil hold windows before surgery, covering pharmacokinetics, priapism risk, anesthesia interactions, and evidence-based perioperative protocols.
Read clinical reviewDoes stopping alprostadil cause rebound ED or withdrawal? A physician-reviewed, evidence-based guide covering what happens physiologically when you discontinue Caverject injections or MUSE suppositories, with primary-literature citations.
Read clinical reviewA clinician-level guide to how temperature, humidity, travel, and seasonal vascular changes affect alprostadil (Caverject/MUSE) storage, dosing, and efficacy in men with refractory erectile dysfunction.
Read clinical reviewA physician-reviewed deep dive into how alprostadil (Caverject, MUSE) affects erectile and sexual function, covering mechanism, clinical trial data, dosing, and patient selection for refractory ED.
Read clinical reviewDoes alprostadil affect sleep architecture? A clinical deep-dive into how intracavernosal and intraurethral alprostadil interact with nocturnal penile tumescence, prostaglandin-mediated sleep pathways, and what that means for men using Caverject or MUSE.
Read clinical reviewA physician-level review of alprostadil's effects on renal hemodynamics, renal protection data, nephrotoxicity risk, and clinical guidance for patients with CKD or renal impairment using Caverject or MUSE.
Read clinical reviewA physician-level guide to safely restarting alprostadil (Caverject intracavernosal injection or MUSE intraurethral suppository) after hospitalization, surgery, cardiovascular events, or other acute illness, with dosing protocols and monitoring criteria.
Read clinical reviewA physician-reviewed, week-by-week guide to alprostadil (Caverject/MUSE) for erectile dysfunction: dosing, expected responses, side effects, and clinical benchmarks drawn from primary literature.
Read clinical review